C07K 2317/90
Characterized by kinetic aspects or by stability of the immunoglobulin
Official title: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
C07K2317/90 (Characterized by kinetic aspects or by stability of the immunoglobulin) appears on 11,618 US grants and 22,610 published applications in this corpus.
Search patents in C07K- Granted patents
- 11,618
- Published applications
- 22,610
- Assignees
- 4,106
- Inventors
- 27,847
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 6 | 0 |
| 1999 | 12 | 0 |
| 2000 | 7 | 0 |
| 2001 | 7 | 2 |
| 2002 | 4 | 24 |
| 2003 | 18 | 72 |
| 2004 | 13 | 75 |
| 2005 | 12 | 103 |
| 2006 | 32 | 163 |
| 2007 | 50 | 177 |
| 2008 | 69 | 203 |
| 2009 | 93 | 366 |
| 2010 | 156 | 423 |
| 2011 | 232 | 521 |
| 2012 | 283 | 590 |
| 2013 | 381 | 714 |
| 2014 | 413 | 923 |
| 2015 | 542 | 887 |
| 2016 | 634 | 1144 |
| 2017 | 725 | 1264 |
| 2018 | 726 | 1218 |
| 2019 | 806 | 1413 |
| 2020 | 943 | 1468 |
| 2021 | 916 | 1767 |
| 2022 | 887 | 1787 |
| 2023 | 830 | 1814 |
| 2024 | 1003 | 2167 |
| 2025 | 1064 | 1918 |
| 2026 | 749 | 1407 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Antibodies binding to alpha-synuclein for therapy and diagnosis6 Oct 2026US 12,753,223 B2AC Immune SA
- Aggrecan binding immunoglobulins6 Oct 2026US 12,753,224 B2Ablynx N. V.
- Anti-MS4A4A antibodies and methods of use thereof6 Oct 2026US 12,753,225 B2Alector LLC
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
- Methods of treating inflammatory diseases8 Oct 2026US 2026/0308246 A1Boehringer Ingelheim International GmbH
- Anti-human interleukin 23 monoclonal antibody and application thereof8 Oct 2026US 2026/0308249 A1Qyuns Therapeutics Co., Ltd.
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Methods for producing members of specific binding pairs893US 5,969,108 ACambridge Antibody Technology Limited · 1999